68 related articles for article (PubMed ID: 11498390)
21. Review of the effects of anti-angiogenic compounds on the epiphyseal growth plate.
Hall AP; Westwood FR; Wadsworth PF
Toxicol Pathol; 2006; 34(2):131-47. PubMed ID: 16537292
[TBL] [Abstract][Full Text] [Related]
22. Tumor anti-angiogenic effect and mechanism of action of delta-tocotrienol.
Shibata A; Nakagawa K; Sookwong P; Tsuzuki T; Oikawa S; Miyazawa T
Biochem Pharmacol; 2008 Aug; 76(3):330-9. PubMed ID: 18599020
[TBL] [Abstract][Full Text] [Related]
23. Anti-angiogenic function of tocotrienol.
Miyazawa T; Shibata A; Nakagawa K; Tsuzuki T
Asia Pac J Clin Nutr; 2008; 17 Suppl 1():253-6. PubMed ID: 18296349
[TBL] [Abstract][Full Text] [Related]
24. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Pradeep CR; Sunila ES; Kuttan G
Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
[TBL] [Abstract][Full Text] [Related]
25. New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12.
Masiero L; Figg WD; Kohn EC
Angiogenesis; 1997; 1(1):23-35. PubMed ID: 14517390
[TBL] [Abstract][Full Text] [Related]
26. Liposomal formulations of anticancer drugs: selectivity and effectiveness.
Massing U; Fuxius S
Drug Resist Updat; 2000 Jun; 3(3):171-177. PubMed ID: 11498382
[TBL] [Abstract][Full Text] [Related]
27. Current Concepts in Multi-Modality Imaging of Solid Tumor Angiogenesis.
Soliman MA; Guccione J; Reiter AM; Moawad AW; Etchison A; Kamel S; Khatchikian AD; Elsayes KM
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33153067
[TBL] [Abstract][Full Text] [Related]
28. Tumor angiogenesis: insights and innovations.
Nussenbaum F; Herman IM
J Oncol; 2010; 2010():132641. PubMed ID: 20445741
[TBL] [Abstract][Full Text] [Related]
29. Recent patents in angiogenesis research.
Nat Biotechnol; 1999 Dec; 17(12):1231. PubMed ID: 10585726
[No Abstract] [Full Text] [Related]
30. Natural compounds target mitochondrial alterations in cancer cell: new avenue for anticancer research.
Pourahmad J; Salimi A; Seydi E
Iran J Pharm Res; 2014; 13(Suppl):1-2. PubMed ID: 24711823
[No Abstract] [Full Text] [Related]
31. Assessment of biochemical factors in blood serum of patients with oral squamous cell carcinoma.
Keshani F; Mahmoodi A; Gholami M; Azmoudeh F
Dent Res J (Isfahan); 2023; 20():81. PubMed ID: 37674571
[TBL] [Abstract][Full Text] [Related]
32. The comparative study of serum iron, copper, and zinc levels between bladder cancer patients and a control group.
Mazdak H; Yazdekhasti F; Movahedian A; Mirkheshti N; Shafieian M
Int Urol Nephrol; 2010 Mar; 42(1):89-93. PubMed ID: 19548109
[TBL] [Abstract][Full Text] [Related]
33. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
34. Colorectal cancer and antiangiogenic therapy: what can be expected in clinical practice?
Mancuso A; Sternberg CN
Crit Rev Oncol Hematol; 2005 Jul; 55(1):67-81. PubMed ID: 15890525
[TBL] [Abstract][Full Text] [Related]
35. Angiogenesis inhibition in solid tumors.
Rosen LS
Cancer J; 2001; 7 Suppl 3():S120-8. PubMed ID: 11779082
[TBL] [Abstract][Full Text] [Related]
36. Angiogenesis--a new target for future therapy.
Pandya NM; Dhalla NS; Santani DD
Vascul Pharmacol; 2006 May; 44(5):265-74. PubMed ID: 16545987
[TBL] [Abstract][Full Text] [Related]
37. Anti-angiogenesis therapy:concepts and importance of dosing schedules in clinical trials.
Mross K
Drug Resist Updat; 2000 Aug; 3(4):223-235. PubMed ID: 11498390
[TBL] [Abstract][Full Text] [Related]
38. Angiogenesis and Cancer Control: From Concept to Therapeutic Trial.
Brem S
Cancer Control; 1999 Oct; 6(5):436-458. PubMed ID: 10758576
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
